BTIG Maintains Buy on Acumen Pharmaceuticals, Lowers Price Target to $1

Benzinga · 2d ago
BTIG analyst Thomas Shrader maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and lowers the price target from $8 to $1.